| A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit MF Beal, D Oakes, I Shoulson, C Henchcliffe, WR Galpern, R Haas, ... JAMA neurology 71 (5), 543-552, 2014 | 314 | 2014 |
| Trial of prasinezumab in early-stage Parkinson’s disease G Pagano, KI Taylor, J Anzures-Cabrera, M Marchesi, T Simuni, K Marek, ... New England Journal of Medicine 387 (5), 421-432, 2022 | 282 | 2022 |
| Effect of deutetrabenazine on chorea among patients with Huntington disease: a randomized clinical trial S Frank, CM Testa, D Stamler, E Kayson, C Davis, MC Edmondson, ... Jama 316 (1), 40-50, 2016 | 208 | 2016 |
| Effect of creatine monohydrate on clinical progression in patients with Parkinson disease: a randomized clinical trial K Kieburtz, BC Tilley, JJ Elm, D Babcock, R Hauser, GW Ross, ... Jama 313 (6), 584-593, 2015 | 182 | 2015 |
| Pioglitazone in early Parkinson's disease: a phase 2, multicentre, double-blind, randomised trial L Neurol Lancet Neurol 14 (8), 795-803, 2015 | 139 | 2015 |
| Integrated safety of levodopa‐carbidopa intestinal gel from prospective clinical trials AE Lang, RL Rodriguez, JT Boyd, S Chouinard, C Zadikoff, AJ Espay, ... Movement Disorders 31 (4), 538-546, 2016 | 121 | 2016 |
| E ffect of levodopa‐carbidopa intestinal gel on dyskinesia in advanced P arkinson's disease patients A Antonini, VSC Fung, JT Boyd, JT Slevin, C Hall, K Chatamra, S Eaton, ... Movement Disorders 31 (4), 530-537, 2016 | 106 | 2016 |
| Effect of urate-elevating inosine on early Parkinson disease progression: the SURE-PD3 randomized clinical trial B Bluett, DM Togasaki, D Mihaila, M Evatt, M Rezak, S Jain, ... Jama 326 (10), 926-939, 2021 | 102 | 2021 |
| Association between change in body mass index, unified Parkinson’s disease rating scale scores, and survival among persons with Parkinson disease: secondary analysis of … AMA Wills, A Pérez, J Wang, X Su, J Morgan, SS Rajan, MA Leehey, ... JAMA neurology 73 (3), 321-328, 2016 | 96 | 2016 |
| Long‐term safety and efficacy of levodopa‐carbidopa intestinal gel in advanced Parkinson's disease HH Fernandez, JT Boyd, VSC Fung, MF Lew, RL Rodriguez, JT Slevin, ... Movement Disorders 33 (6), 928-936, 2018 | 90 | 2018 |
| Configuration and performance of the ATLAS b-jet triggers in Run 2 ATLAS Collaboration atlas. publications@ cern. ch, G Aad, B Abbott, ... The European Physical Journal C 81 (12), 1087, 2021 | 75 | 2021 |
| Incidence of malignant neoplasms among HIV-infected persons in Scotland GM Allardice, DJ Hole, DH Brewster, J Boyd, DJ Goldberg British Journal of Cancer 89 (3), 505-507, 2003 | 69 | 2003 |
| A phase II study to evaluate the safety and efficacy of prasinezumab in early Parkinson's disease (PASADENA): rationale, design, and baseline data G Pagano, FG Boess, KI Taylor, B Ricci, B Mollenhauer, W Poewe, ... Frontiers in neurology 12, 705407, 2021 | 66 | 2021 |
| Septal dysembryoplastic neuroepithelial tumor: a comprehensive clinical, imaging, histopathologic, and molecular analysis JCH Chiang, JH Harreld, R Tanaka, X Li, J Wen, C Zhang, DR Boué, ... Neuro-oncology 21 (6), 800-808, 2019 | 63 | 2019 |
| Predictors of weight loss in early treated Parkinson’s disease from the NET-PD LS-1 cohort AM Wills, R Li, A Pérez, X Ren, J Boyd, NINDS NET-PD Investigators Journal of neurology 264, 1746-1753, 2017 | 46 | 2017 |
| Treatment of impulse control disorders in Parkinson’s disease: practical considerations and future directions A Ramirez-Zamora, L Gee, J Boyd, J Biller Expert Review of Neurotherapeutics 16 (4), 389-399, 2016 | 46 | 2016 |
| Safety and efficacy of valbenazine for the treatment of chorea associated with Huntington's disease (KINECT-HD): a phase 3, randomised, double-blind, placebo-controlled trial EF Stimming, DO Claassen, E Kayson, J Goldstein, R Mehanna, H Zhang, ... The Lancet Neurology 22 (6), 494-504, 2023 | 45 | 2023 |
| Association of metabolic syndrome and change in Unified Parkinson's Disease Rating Scale scores M Leehey, S Luo, S Sharma, AMA Wills, JL Bainbridge, PS Wong, ... Neurology 89 (17), 1789-1794, 2017 | 39 | 2017 |
| Factors associated with falling in early, treated Parkinson's disease: The NET-PD LS1 cohort KL Chou, JJ Elm, CL Wielinski, DK Simon, MJ Aminoff, CW Christine, ... Journal of the neurological sciences 377, 137-143, 2017 | 37 | 2017 |
| Longer duration of MAO-B inhibitor exposure is associated with less clinical decline in Parkinson’s disease: an analysis of NET-PD LS1 RA Hauser, R Li, A Pérez, X Ren, D Weintraub, J Elm, JL Goudreau, ... Journal of Parkinson's Disease 7 (1), 117-127, 2017 | 34 | 2017 |
Adriana PerezThe University of Texas Health Science Center at Houston在 uth.tmc.edu 的电子邮件经过验证
